Stock-Based Compensation (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2026	Mar. 31, 2025	Sep. 30, 2025	Dec. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock Shares Reserved		16,615,246			11,437,462
Common stock, shares issued		80,088,931			79,991,768
General and administrative expenses	[1]	$ 6,377	$ 2,502
Stock options for accelerated vesting		1,730,153
Number of options exercised		222,939
weighted-average grant granted		$ 7.52
Weighted average grant date fair value, Vested		4.1
Weighted average grant date fair value, Forfeited		$ 6.57
Weighted average period, unvested common stock options		3 years 2 months 12 days
Unrecognized stock based expense		$ 61,500
Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average period, unvested common stock options		3 years 9 months 18 days
Unrecognized stock based expense		$ 3,700
BridgeBio Pharma
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
General and administrative expenses		$ 7,800
Stock Option And Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock Shares Reserved		1,521,834
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock Shares Reserved		1,808,313
Reduction in fair valuse percentage				85.00%
Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock Shares Reserved		852,500
2016 Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common Stock Shares Reserved		0
Number of options vested		1,507,214

[1] General and administrative expenses include related party amounts of $40 and $168 for the three months ended March 31, 2026 and 2025, respectively.